[Phosphodiesterase III inhibitor--characteristics, mechanisms of action, pharmacokinetics, indications, contraindications, clinical trials, and side effects]

Nihon Rinsho. 2007 May 28:65 Suppl 5:43-8.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • 3',5'-Cyclic-AMP Phosphodiesterases / antagonists & inhibitors*
  • Cardiotonic Agents* / administration & dosage
  • Cardiotonic Agents* / pharmacokinetics
  • Cardiotonic Agents* / pharmacology
  • Clinical Trials as Topic
  • Contraindications
  • Cyclic AMP / metabolism
  • Cyclic Nucleotide Phosphodiesterases, Type 3
  • Humans
  • Imidazoles
  • Milrinone
  • Phosphodiesterase Inhibitors* / administration & dosage
  • Phosphodiesterase Inhibitors* / pharmacokinetics
  • Phosphodiesterase Inhibitors* / pharmacology
  • Pyridazines
  • Pyridones

Substances

  • Cardiotonic Agents
  • Imidazoles
  • Phosphodiesterase Inhibitors
  • Pyridazines
  • Pyridones
  • pimobendan
  • olprinone
  • Cyclic AMP
  • 3',5'-Cyclic-AMP Phosphodiesterases
  • Cyclic Nucleotide Phosphodiesterases, Type 3
  • Milrinone